SPN-812: Phase IIa data

A double-blind, placebo-controlled, U.S. Phase IIa trial in 52 adults with ADHD showed that thrice-daily oral SPN-812 for 5 weeks was well tolerated and met the primary endpoint of safety. On secondar...